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AbstrAct
The anti-epidermal growth factor receptor (EGFR) 
monoclonal antibody cetuximab in combination with 
chemotherapy is a standard of care in the first-line 
treatment of RAS wild-type (wt) metastatic colorectal 
cancer (mCRC) and has demonstrated efficacy in later 
lines. Progressive disease (PD) occurs when tumours 
develop resistance to a therapy, although controversy 
remains about whether PD on a combination of 
chemotherapy and targeted agents implies resistance to 
both components. Here, we propose that some patients 
may gain additional clinical benefit from the reuse 
of cetuximab after having PD on regimens including 
cetuximab in an earlier treatment line. We conducted a 
non-systematic literature search in PubMed and reviewed 
published and ongoing clinical trials, focusing on later-
line cetuximab reuse in patients with mCRC. Evidence 
from multiple studies suggests that cetuximab can be an 
efficacious and tolerable treatment when continued or 
when fit patients with mCRC are retreated with it after 
a break from anti-EGFR therapy. Furthermore, on the 
basis of available preclinical and clinical evidence, we 
propose that longitudinal monitoring of RAS status may 
identify patients suitable for such a strategy. Patients who 
experience progression on cetuximab plus chemotherapy 
but have maintained RAS wt tumour status may benefit 
from continuation of cetuximab with a chemotherapy 
backbone switch because they have probably developed 
resistance to the chemotherapeutic agents rather than the 
biologic component of the regimen. Conversely, patients 
whose disease progresses on cetuximab-based therapy 
due to drug-selected clonal expansion of RAS-mutant 
tumour cells may regain sensitivity to cetuximab following 
a defined break from anti-EGFR therapy. Looking to the 
future, we propose that RAS status determination at 
disease progression by liquid, needle or excisional biopsy 
may identify patients eligible for cetuximab continuation 
and rechallenge. With this approach, treatment benefit 
can be extended, adding to established continuum-of-care 
strategies in patients with mCRC.
IntroduCtIon
Colorectal cancer is the fourth most prev-
alent cancer type in the world and causes 
nearly 700 000 deaths per year worldwide.1 
Patients diagnosed with metastatic colorectal 
cancer (mCRC) have a limited number of 
systemic therapeutic options available as well 
as local therapies, such as resection, ablation 
or transhepatic irradiation via the injection 
of yttrium 90. Encouragingly, the median 
overall survival (OS) in recent phase III first-
line trials in RAS wild-type (wt) mCRC now 
exceeds 30 months.2–5 
The available biologic agents usually 
planned for first-line therapy include the 
epidermal growth factor receptor (EGFR) 
monoclonal antibodies (mAbs) cetuximab or 
panitumumab and the anti–vascular endothe-
lial growth factor (VEGF) agent bevacizumab. 
All three agents, plus additional targeted 
drugs such as aflibercept (VEGF inhibitor), 
regorafenib (receptor tyrosine kinase inhib-
itor) and ramucirumab (anti-VEGF receptor 
2), have also shown efficacy in the second and 
later lines of therapy.6–12 Mounting evidence 
from randomised, phase III trials and 
meta-analyses suggests that many patients with 
RAS wt tumours may experience improved 
survival outcomes when chemotherapy is 
combined with cetuximab compared with 
combination with bevacizumab in the first-
line setting.3 5 13–15 Retrospective analyses and 
meta-analyses have shown that the survival 
benefit is especially pronounced in patients 
with RAS wt, left-sided primary tumours.16–19 
Although patients with right-sided tumours 
appear to derive less significant benefits from 
all available therapies for mCRC in terms 
of overall response rate (ORR), progres-
sion-free survival (PFS) and overall survival 
(OS) than do those with tumours originating 
in the left side of the colon,18–20 some patients 
may benefit from cetuximab-based therapy if 
the goal of treatment is response and subse-
quent cytoreduction.18 19 Indeed, cetuximab 
has been shown to yield a very good ORR, 
early tumour shrinkage (ETS) and depth of 
response in patients with RAS wt tumours. 
Such alternative metrics of response have been 
shown to be associated with improvements in 
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survival5 compared with bevacizumab in the randomised, 
phase III, first-line FIRE-3 trial (5-FU, Folinic Acid and 
Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI 
Plus Bevacizumab in First Line Treatment Colorectal 
Cancer), which evaluated patients with RAS wt mCRC.5 21
Currently, amplifications and mutations in several 
genes other than RAS, detected pretherapy, are also 
being investigated as potential predictive  biomarkers 
of response to anti-EGFR therapy. The BRAF V600E 
variant22 23 appears to be a negative prognostic marker, 
but due to the relatively low number of colorectal cancers 
harbouring BRAF mutations (and as not all BRAF muta-
tions confer resistance), controversy remains regarding 
the impact of this finding.24 Other markers of interest 
include alterations in the EGFR pathway, mutations in 
the phosphatidylinositol-4,5-bisphosphate 3-kinase cata-
lytic subunit α gene (PIK3CA) and amplification of the 
human epidermal growth factor receptor 2 gene, HER2 
(mostly in patients with anti-EGFR-refractory, RAS wt 
disease).25–33 Furthermore, hypermethylation of tumour 
DNA appears to be potentially predictive of poorer clin-
ical outcomes in patients receiving anti-EGFR therapy.34 35 
The individual frequencies of all of these mutations and 
amplifications are low,25 27 33 36 37 and conflicting data exist 
regarding whether several of these genomic alterations 
are true biomarkers for cetuximab resistance. Additional 
biomarkers that are currently being explored as predic-
tive of cetuximab response include VEGF2, MET (mesen-
chymal-epithelial transition factor mutations), fibroblast 
growth factor receptor mutations, platelet-derived 
growth factor, epiregulin, amphiregulin, mIR 31–3 p and 
hepatocyte growth factor.29 30 38–46 Presently, however, RAS 
mutations and tumour sidedness remain the only robust 
factors when selecting patients for anti-EGFR therapy in 
accordance with the drug labels for both cetuximab and 
panitumumab and the established international guide-
lines10 47 and are the most informative for treatment deci-
sions in mCRC.
Colorectal tumours that are RAS wt at baseline can 
evolve resistance to anti-EGFR therapy via a RAS status 
‘shift’ to mutated status to escape the drug’s effects.39 It 
is now known that this change occurs when the RAS wt 
tumour cell population is diminished during anti-EGFR 
therapy, while pre-existing or newly evolving RAS-mutant 
subclones can proliferate and become detectable by DNA 
testing.27 29 48 Other gene mutations, including in BRAF, 
may be subject to the same tumour heterogeneity prin-
ciples and drug selection dynamics. Another key mecha-
nism of acquired resistance that occurs in approximately 
25% of patients treated with anti-EGFR therapy are muta-
tions in the extracellular domain (ECD) of EGFR that 
prevent further binding of anti-EGFR mAbs to EGFR. 
Importantly, EGFR ECD alterations emerge as a means 
for cancer cells to circumvent EGFR blockade—acquired 
resistance—and do not apparently exist as a mechanism 
of primary resistance in anti-EGFR-naïve patients. Inter-
estingly, the frequency and type of EGFR ECD mutation 
varies, depending on previous treatment with cetuximab 
or panitumumab, and each different EGFR ECD muta-
tion may potentially confer resistance to cetuximab only, 
panitumumab only or both mAbs.28 49–51 Finally, these 
mutations frequently coexist in the same patient at the 
moment of disease progression, as multiple RAS, BRAF 
and EGFR clones are detectable in cell-free circulating 
tumour DNA (ctDNA) by liquid biopsy.29 52
Extending the continuum of care through the delivery 
of as many lines of efficacious therapy as possible is 
desirable so that patients with progressive disease (PD) 
have multiple potentially beneficial treatment options 
to explore before transitioning into palliative care. For 
mCRC, however, patients with RAS wt tumours are gener-
ally assigned two lines of intensive therapy. They receive 
a first-line anti-EGFR mAb (cetuximab or panitumumab) 
or bevacizumab plus doublet/triplet chemotherapy 
(5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), 
5-fluorouracil, leucovorin and irinotecan (FOLFIRI), 
5-fluorouracil, leucovorin, oxaliplatin and irino-
tecan (FOLFOXIRI)). This is followed by second-line 
‘switch’ of either the biologic, the chemotherapy back-
bone or both on PD. For patients who respond to a 
therapy and whose disease does not progress but require 
an interruption due to their preference or recovery from 
drug toxicity or surgery, a pause-and-resume (commonly 
referred to as stop-and-go or reintroduction/re-exposi-
tion) schedule of a biologic with or without chemotherapy 
can help them to complete the full planned treatment 
and maintenance period.53–55
Multiple studies with dedicated second-line, third-line 
or mixed second-line and further-line patient popula-
tions have indicated improved survival and ORR with 
cetuximab monotherapy or cetuximab in combination 
with chemotherapy56–62 and with panitumumab mono-
therapy or panitumumab plus chemotherapy.57 63–67 
Overall, all current guidelines conclude that patients with 
RAS wt mCRC who do not receive a biologic in the first 
line (but are fit enough to receive it in later lines) should 
be considered candidates for an anti-EGFR therapy in the 
next available line. Then, in the third line and beyond, 
patients are usually offered other targeted or chemother-
apy-based interventions, often with limited expectations 
of clinical benefit. This is because, currently, it is widely 
accepted that after patients with left-sided, RAS wt mCRC 
have received an anti-EGFR antibody and bevacizumab 
sequentially (in either order) and experience progres-
sion, their disease is permanently resistant to both the 
biologic and cytotoxic agents that have been adminis-
tered. However, this conclusion may not be accurate for 
all patients as some tumours may retain sensitivity to the 
targeted agent (although becoming resistant to the cyto-
toxic agents in the chemotherapy programme) or regain 
sensitivity after a ‘treatment break’ from those specific 
agents.68–73 Thus, many patients exhaust standard treat-
ment options while maintaining a good performance 
status and are therefore not ready to transition to a solely 
palliative-care approach. Here, we review the evidence for 
continuation or reuse strategies beyond the first line with 
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cetuximab, a well-established agent for RAS wt mCRC, as 
a method of expanding the therapeutic options available 
to patients and maximising the number of (potentially 
curative) therapeutic lines before the initiation of pallia-
tive care (figure 1).
Notably, the bulk of available evidence for anti-EGFR 
retreatment stems from trials that use cetuximab rather 
than panitumumab. Furthermore, the two mAbs are 
known to behave somewhat differently in the context of 
treatment sequencing.74–81
Selecting cetuximab-eligible patients by liquid biopsy testing
Because the predominance of specific tumour cell 
subclones is dictated by selection pressures such as 
targeted therapy, retreatment strategies with cetuximab 
could be individualised with longitudinal tracking of 
detectable RAS mutations (and any future confirmed 
predictive biomarker of response) as a measure of poten-
tial sensitivity to cetuximab.27 29 30 39 51 Depending on the 
location of metastatic disease in some patients, traditional 
tumour needle or excisional biopsies may be invasive 
and risky. Thus, a less invasive method is desirable (eg, 
liver needle aspirates or plasma sampling). This ‘liquid’ 
biopsy can fulfil the retesting requirement by providing 
a non-invasive method for the detection and analysis of 
ctDNA. Of note, >75% of patients with advanced CRC 
have been shown to have detectable ctDNA (79.8% in 
the RASANC study (RAS Mutation Testing in the Circu-
lating Blood of Patients With Metastatic Colorectal 
Cancer)),82 83 and multiple useful platforms currently 
exist to allow the identification of tumour mutations via 
PCR of ctDNA: digital PCR84; digital next-generation 
sequencing85; BEAMing (beads, emulsion, amplification 
and magnetics)86; pyrophosphorolysis-activated polymeri-
sation87; personalised profiling by deep sequencing88 and 
tagged-amplicon deep sequencing.89 Liquid biopsies have 
proven to be clinically robust. In a cohort of 98 patients 
with mCRC, Schmiegel et al90 used BEAMing to test for 
RAS tumour mutation status and found 91.8% concord-
ance between ctDNA and tissue-based testing. Similarly, 
Vidal et al91 detected a 93% concordance rate in a cohort 
of 115 patients with mCRC. In the prospective, multi-
centre RASANC study (n=425), the concordance rate was 
83.7% in the overall population and was even higher in 
patients with their primary tumour in place, liver metas-
tasis and synchronous disease.83
Overall, RAS is the only widely recognised predictive 
molecular biomarker of cetuximab response and the only 
biomarker with extensive evidence of a high concordance 
between tissue-based and blood-based testing. However, 
we will refer to patients under consideration in this article 
more generally as ‘cetuximab-eligible patients’, for whom 
this definition is subject to change as additional research 
is published in the coming years. Furthermore, no 
subgroup analyses by tumour location are available for the 
studies on treatment beyond progression discussed here. 
However, we use the term ‘cetuximab-eligible’ to encom-
pass optimal candidates for cetuximab-based therapy, 
including those with left-sided, RAS wt mCRC, and those 
with right-sided, RAS wt mCRC for whom cytoreduction is 
a key treatment goal, or who have previously responded 
to cetuximab-based therapy.
Figure 1 A proposed treatment model for the decision-making process when choosing between cetuximab continuation 
vs rechallenge. aTypically patients with left-sided, RAS wt mCRC or those with right-sided, RAS wt mCRC in need of rapid 
tumour shrinkage. bBy liquid biopsy. cOther evidence-based biomarkers can also be included in the panel of tests when 
feasible. EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil, leucovorin and irinotecan; FOLFOX, 5-fluorouracil, 
leucovorin and oxaliplatin; mut, mutant; PD, progressive disease; wt, wild-type.
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Continuation treatment strategy
Patients who received and progressed on cetuximab-con-
taining regimens in the preceding line may retain 
cetuximab sensitivity,68–70 92 having instead become 
refractory to the chemotherapy backbone (table 1). In 
a study conducted by Feng et al,69 patients with RAS wt 
tumours whose disease progressed during first-line cetux-
imab plus chemotherapy were randomised to receive a 
different chemotherapy backbone with or without cetux-
imab as second-line treatment. The cetuximab-contin-
uation group demonstrated better PFS, OS and disease 
control rates and a potentially better ORR than did the 
chemotherapy-only (no cetuximab continuation) group. 
Extended RAS analysis for the retrospective study revealed 
that baseline RAS wt status correlated with response to 
continuation of cetuximab; ETS during first-line cetux-
imab-based treatment also correlated with improved 
efficacy outcomes during second-line cetuximab contin-
uation. Additionally, Ciardiello et al68 found evidence 
of a survival benefit from continued cetuximab plus 
FOLFOX in patients whose disease progressed during 
first-line cetuximab plus FOLFIRI and had KRAS/N-
RAS/BRAF/PIK3CA wt tumours. Both Feng et al and 
Ciardiello et al switched chemotherapy backbones when 
going from first-line to second-line treatment and used a 
chemotherapy switch alone as a comparator arm. There-
fore, if sensitivity to cetuximab was preserved, switching 
to a non-cross-resistant chemotherapy backbone after PD 
could reinvigorate responsiveness. No new safety findings 
were identified from cetuximab continuation in any of 
these studies.68 69 72
By contrast, the majority of panitumumab retreat-
ment trials have followed the stop-and-go (re-exposi-
tion) model rather than continuation (ie, patients did 
not experience progression on panitumumab immedi-
ately before retreatment).93 94 For example, a phase II 
Japanese study examining the administration of panitu-
mumab plus chemotherapy following six cycles of first-
line panitumumab plus FOLFOX is currently ongoing 
(SAPPHIRE (Safety and Efficacy Study of mFOLFOX6 
+ Panitumumab Combination Therapy and 5-FU/LV + 
Panitumumab Combination Therapy in Patients With 
Chemotherapy-naïve Unresectable Advanced Recurrent 
Colorectal Carcinoma); NCT02337946); therapy prolon-
gation appears to be planned in the absence of PD, and the 
focus of the study is the feasibility of oxaliplatin treatment 
extension rather than panitumumab continuation.95
As has been demonstrated, deriving maximum benefit 
from cetuximab before introducing a biologic switch 
could extend the number of potentially efficacious 
lines of therapy for fit patients and thereby optimise the 
continuum of care.69 We advance the hypothesis that 
using ETS during first-line cetuximab and extended RAS 
analysis at PD can enable effective patient selection for 
this therapeutic strategy (figure 1).69 For patients whose 
tumours transition from cetuximab sensitive to insensi-
tive (eg, by converting to RAS mutant), a treatment break T
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followed by cetuximab rechallenge may allow another 
means of extending the continuum of care. Here, again, 
liquid biopsy for RAS status may prove highly informative.
rechallenge treatment strategy
Evidence of rechallenge therapy in multiple tumour 
types has been published.96–98 Because no conclusive 
randomised trials have been completed to test whether 
longitudinal RAS status monitoring can identify patients 
who regain cetuximab sensitivity, we will outline the avail-
able preliminary preclinical (biological) and clinical 
support for this treatment approach.
Biological evidence
Tumour cells in a patient who is receiving treatment are 
constantly under selection pressures from the therapy 
being administered. Studies have suggested that mutations 
conferring resistance to therapy can arise during treat-
ment. For example, when retested for (K)RAS status, >50% 
of patients with acquired resistance to first-line anti-EGFR 
therapy demonstrate a ‘switched’ status from (K)RAS wt to 
mutant,27 29–31 39 51 82 and the opposite observation (tumours 
switching from mutant KRAS to undetectable mutant status) 
has been made during bevacizumab treatment.99 Impor-
tantly, from studies monitoring plasma levels of RAS-mutant 
ctDNA, even short ‘holidays’ off anti-EGFR therapy may 
restore tumours to a cetuximab-sensitive state.39 68 100 Intra-
tumour heterogeneity and drug-selected clonal evolution 
can account for these ‘switches’ (figure 2). The suggested 
mechanism for such a switch is the constant presence of 
a small number of RAS-mutant cell subclones persisting in 
the tumours, rather than de novo RAS mutations appearing 
in previously RAS wt tumour cells.73 Thus, a tumour can 
contain predominantly RAS wt clones, test as RAS wt and 
respond to cetuximab treatment until the RAS wt clones are 
depleted. In this environment, the RAS-mutant clones have 
the opportunity to continue proliferating and surviving and 
thus come to represent the dominant tumour subclonal 
population.51 100 Indeed, an in vitro study of two separate 
KRAS wt colorectal cancer cell populations showed that, 
under selection pressure from cetuximab treatment, the 
surviving population developed KRAS amplifications; when 
allowed to proliferate for 160 days without additional cetux-
imab treatment, the population of cells achieved signifi-
cantly lower levels of KRAS amplification.39
The principles of clonal selection likely also apply to 
other mechanisms of resistance to anti-EGFR therapy.29 
Indeed, a number of genetic modifications beyond RAS 
have been related to acquired drug resistance to anti-
EGFR therapy. Interestingly, most of these different genetic 
aberrations are related to or have influence on MEK-ERK 
pathway activity.101 The reversion of these additional resis-
tance mechanisms during the anti-EGFR therapy break is 
controversial and not yet clearly demonstrated. Finally, it 
should be noted that even if arising on-treatment mutations 
have been identified, the exact threshold associated with 
resistance to anti-EGFR therapy has not been established, 
and some patients continue to experience disease control 
for several months after RAS-mutant clones emerge.51 102 
Overall, there is a strong biological rationale for cetuximab 
rechallenge.
Clinical evidence
There is currently abundant clinical evidence for RAS status 
switch103 104 but little evidence analysing the direct relation-
ship between a return to undetectable RAS-mutant status 
and a resensitisation to cetuximab.39 However, there exists 
clinical evidence for the feasibility of cetuximab rechallenge 
in patients with baseline (K)RAS wt mCRC whose disease 
Figure 2 A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RASa 
wt tumours during anti-EGFR therapy. aAdditional or secondary acquired mechanisms of resistance can also be driven 
by mutations in the extracellular domain of the EGFR, and other potential biomarkers continue to be investigated. EGFR, 
epidermal growth factor receptor; mut, mutant; wt, wild-type.
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progresses on first-line anti-EGFR therapy plus chemo-
therapy; such patients are usually rechallenged with cetux-
imab with or without chemotherapy in the later-line setting 
after ≥3 months of therapy that does not contain an anti-
EGFR targeted agent. In a study by Santini et al73 (table 2), 39 
patients whose disease had previously progressed on cetux-
imab plus irinotecan-based therapy were rechallenged with 
cetuximab plus irinotecan after a treatment break during 
which they received non-irinotecan-based chemotherapy 
alone. The median treatment break for these patients was 6 
months, and patients had received a median of four lines of 
therapy prior to study enrolment. Nevertheless, median PFS 
was 6.6 months, and the ORR with cetuximab plus irino-
tecan rechallenge was 53.8% and included two complete 
responses. Stable disease was achieved by a further 35.9%, 
for a total disease control rate of 89.7%. Finally, in a recent 
prospective study by Gruppo Oncologico del Nord Ovest 
in Italy, the CRICKET study (Cetuximab Rechallenge in 
Irinotecan-pretreated mCRC,  KRAS ,  NRAS   and  BRAF   
Wild-type Treated in 1st Line With Anti-EGFR Therapy), 27 
patients with mCRC were to be treated with cetuximab plus 
FOLFIRI or FOLFOXIRI in the first line followed by bevaci-
zumab plus oxaliplatin-based chemotherapy in the second 
line and cetuximab plus irinotecan rechallenge in the third 
line. The third-line ORR was 23%, with 54% of patients 
experiencing disease control, and the study met its primary 
end point.105 Rechallenge treatment was well tolerated in 
all studies. The prospective biological determinations of 
ctDNA are ongoing.
Also noteworthy is a retrospective study by Liu et al71an-
alysing patients with baseline KRAS wt status who received 
cetuximab (n=76) or cetuximab plus erlotinib (n=13) after 
a median of 4.57 months of treatment break from anti-
EGFR therapy. Patients who had previously responded 
to anti-EGFR therapy achieved a median PFS of nearly 5 
months.71 Rechallenge treatment was found to be well 
tolerated. Additionally, Liu et al71 suggested that the length 
of the anti-EGFR treatment interval may be related to the 
responsiveness of patients to rechallenge, on the basis of 
the observation that patients whose break from anti-EGFR 
therapy was longer than the median appeared more likely 
to respond. Overall, these studies suggest that good ORR 
and PFS can be achieved with cetuximab rechallenge in a 
patient population that has experienced progression on 
many prior lines of therapy, and these observations under-
score the importance of optimising and extending the 
continuum of care.
Table 2 Evidence for cetuximab rechallenge in patients with KRAS wt mCRC whose disease has previously progressed 
on cetuximab plus chemotherapy treatment and received who have received at least one line of additional, non–anti-EGFR 
therapy
Study Previous regimen
Liu et al71 (2015; 
retrospective study)
Summary:
 ► Patients with KRAS wt mCRC received anti-EGFR therapy (cetuximab or panitumumab) based 
treatment
 – When PD occurred, patients received a break from anti-EGFR therapy (median duration, 4.6 
months)
 – 80 patients were retreated with cetuximab ± CT ± other targeted agents
Results:
 ► 58.0% (CR/PR/SD)
 ► Patients who responded to prior anti-EGFR therapy were more likely to obtain clinical benefit upon 
rechallenge (PFS, 4.9 vs 2.5 months; P=0.007)
 ► The clinical benefit rate on rechallenge showed a marginally significant association with interval time 
between the two anti-EGFR based therapies (P=0.053)
Santini et al73 (2012) Summary:
 ► Patients with KRAS wt mCRC received anti-EGFR therapy (cetuximab) + (FOLF)IRI
 – When PD occurred, patients received a break from anti-EGFR therapy (median duration, 6.0 
months)
 – 39 patients were retreated with cetuximab + (FOLF)IRI
Results:
 ► ORR, 53.8% (plus 35.9% SD)
 ► Median PFS, 6.6 months
 ► Interval effect not discussed
Rossini et al105  (2017; 
CRICKET)
Summary:
 ► Patients with RAS/BRAF wt mCRC who became resistant to first-line cetuximab + irinotecan
 ► Treated with third-line cetuximab + irinotecan
 ► N=26
Results:
 ► ORR, 23% (plus 31% SD)
CR, complete response; CT, chemotherapy; EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; IRI, 
irinotecan; mCRC, metastatic colorectal cancer; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, 
partial response; SD, stable disease; wt, wild-type.
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One limitation of both the retrospective trial by Liu et al 
and prospective trial by Santini et al (except the CRICKET 
study) is that enrolment occurred prior to the standardisa-
tion of extended RAS analysis; therefore, data are not yet 
available for patients with RAS wt tumours. Furthermore, 
no retest was conducted for RAS status as liquid biopsy had 
not yet been validated. However, the fact that a patient 
population with previous progression on cetuximab-based 
therapy can achieve a median PFS of 5–6 months with 
rechallenge suggests that sensitivity to cetuximab, at least 
in some patients, can be meaningfully regained. However, 
certain selection criteria could be recommended here, such 
as establishing a minimum recommended treatment break 
length or selecting patients who had a durable response 
or disease stabilisation during the last cetuximab-based 
treatment.
Additional evidence for cetuximab rechallenge therapy 
can be found in case studies.103 106 107 Of note, Siravegna et 
al39 identified a patient with mCRC who initially achieved 
stable disease for 6 months with cetuximab plus irino-
tecan; on disease progression, the patient received XELOX 
(capecitabine and oxaliplatin) and experienced progres-
sion again after 3 months. The patient was then rechal-
lenged with cetuximab plus irinotecan and achieved a 
partial response.
Notably, anti-EGFR rechallenge strategy data are avail-
able primarily for cetuximab but not for panitumumab. 
The limited data on panitumumab rechallenge come from 
two case reports by Siravegna et al,39 in which the patients 
achieved a partial response and stable disease when 
retreated with panitumumab following RAS mutational 
status switch and reversal. Additionally, Hata et al108 describe 
two patients with good outcomes when retreated with pani-
tumumab after a line of non-anti-EGFR therapy, although 
neither patient had experienced PD during prior pani-
tumumab-based therapy (in the earlier line, one stopped 
panitumumab treatment due to toxicity, and the other 
had completed the determined number of panitumumab 
cycles). Finally, some reports have described responses 
to panitumumab treatment after failure of cetuximab, 
primarily in heavily pretreated patients.109 110
Ongoing studies, including additional analyses of 
the CRICKET study (NCT02296203), a study in Japan 
(UMIN000016439), and a similar study in Israel (trial iden-
tification number not yet available), will help determine 
whether this treatment strategy is feasible and which patients 
are most suitable for this approach. Although no completed 
trial to date has tracked RAS mutational status longitudi-
nally throughout treatment, progression and rechallenge, 
a highly relevant phase III trial (FIRE-4; NCT02934529) is 
currently being conducted. This study has a planned enrol-
ment of 550 patients with RAS wt mCRC who will receive 
first-line cetuximab-based therapy and third-line cetuximab 
rechallenge. This trial specifically includes non-invasive 
(liquid biopsy) RAS status assessment on PD and will thus 
directly test our proposal that longitudinal RAS status moni-
toring can be a tool in selecting patients suitable for cetux-
imab rechallenge after a treatment break. As of this writing, 
the FIRE-4 study is actively recruiting patients and has an 
estimated completion date of March 2022.
Although the studies we have reviewed have reported 
good clinical efficacy with cetuximab continuation and 
rechallenge, and evidence of a possible connection to RAS 
status switch, the treatment strategies outlined in figure 1 
are not considered routine practice at this time. As new 
evidence emerges and patient selection becomes more 
refined, these strategies are likely to become valuable for 
oncologists looking to extend the continuum of poten-
tially curative therapy for patients with a good performance 
status. Finally, it is also possible that other mechanisms of 
acquired resistance to cetuximab (eg, EGFR,27 51 HER2/MET 
amplifications,104 KRAS/NRAS, BRAF, PIK3CA111 112) arise in 
the same way and coexist in the same tumour. Some may be 
subject to similar dynamics of clonal selection under pres-
sure, and, therefore, return to predominantly wt status after 
the anti-EGFR treatment is halted (except for EGFR ECD 
mutations, which do not pre-exist in untreated tumours but 
emerge de novo under anti-EGFR treatment and persist in 
the tumour).51
ConCluSIon
Anti-EGFR mAb plus chemotherapy is a standard of care in 
the first-line setting for patients with RAS wt mCRC, with a 
particular benefit for patients with left-sided tumours.10 11 
Importantly, cetuximab can also be a significant component 
in second-line and later-line treatments, thereby affording 
additional treatment opportunities to suitable patients and 
optimising and extending the continuum of care. In cetux-
imab-naïve patients, later-line treatment with cetuximab 
plus chemotherapy generally results in efficacy benefits 
over chemotherapy alone.56 59 Use of cetuximab mono-
therapy or cetuximab plus chemotherapy in second-line 
and later-line mCRC does not yield any new safety signals, 
thereby further supporting its utility.56 57 59 113 114
Notably, patients do not have to be cetuximab naïve to 
extract benefits from second-line and later-line use of cetux-
imab.68–70 72 Treatment with cetuximab beyond progression 
in conjunction with a different chemotherapy backbone 
results in efficacy benefits, although this approach still 
needs to be confirmed in a large-scale clinical study. Evalua-
tion of tumour RAS status on progression on first-line cetux-
imab plus chemotherapy may be informative in identifying 
candidates for continuation of cetuximab after the RAS 
threshold relevant for clinical resistance has been deter-
mined. Additionally, patients whose tumours ‘switched’ 
to RAS-mutant status following previous cetuximab-based 
therapy can regain cetuximab sensitivity and be rechal-
lenged with cetuximab after a ‘holiday’ of several months, 
with renewed efficacy benefits.71 73 Liquid biopsy-based RAS 
testing will be needed to select for patients who can receive 
continuation cetuximab in the second line versus a treat-
ment break (from anti-EGFR therapy) followed by rechal-
lenge in third or further lines. We anticipate the results 
of trials such as FIRE-4, which may solidify the concept of 
cetuximab rechallenge as a routine therapeutic strategy 
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to optimise and extend the continuum of care in patients 
with mCRC. To this end, further research into additional 
biomarkers of response to anti-EGFR agents will ensure 
definition of the optimal patient populations for these strat-
egies, thereby maximising the continuum of care.
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